The price trend for Oncorus, Inc. (ONCR) has been bearish lately and the stock has lost 20.4% over the past four weeks. However, the formation of a hammer chart pattern in its last trading session ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Fintel reports that Arkin Moshe has filed a 13G/A form with the SEC disclosing ownership of 2.51MM shares of Oncorus Inc (ONCR). This represents 9.66% of the company. In their previous filing dated ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

Oncorus, Inc. (ONCR) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...

-- Renowned academic and industry leader brings deep expertise in oncology translational research and drug development, including pioneering work at Merck on KEYTRUDA® (pembrolizumab) -- CAMBRIDGE, ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oncorus, Inc., an oncolytic virus company focused on driving innovation to transform outcomes for cancer patients, announced today the nomination of ONCR-177, a next ...

ONCR-719 is uniquely engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry, which is highly expressed in glioblastoma multiforme (GBM); data show that the canonical ...

Shares of Oncorus ONCR were down 37.1% on Jun 2 after management announced that the company’s board of directors approved a workforce reduction of around 55 employees, which represents “substantially ...